Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891871 | 0.84 | BACE1 (0.38) | — | |
| SCHEMBL892224 | 0.82 | BACE1 (0.48) | — | |
| SCHEMBL891892 | 0.73 | BACE1 (0.51) | — | |
| SCHEMBL875232 | 0.69 | BCHE (0.47) | LMNAALDH1A1CYP3A4MAPK1HTR7 | |
| SCHEMBL10576219 | 0.67 | AKR1B1 (0.51) | AKR1B1 | |
| SCHEMBL11338887 | 0.65 | AKR1B10 (0.66) | AKR1B1 | |
| SCHEMBL7892214 | 0.65 | BACE1 (0.61) | — | |
| SCHEMBL10576683 | 0.63 | PDE7A (0.44) | PDE7ALMNAAKR1B1 | |
| SCHEMBL877186 | 0.60 | TNF (0.39) | PDE7ALMNAAKR1B1ADAM17OPRK1 | |
| SCHEMBL8273477 | 0.60 | GAA (0.57) | PDE7AAKR1B1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PDE7A 984/4885LMNA 616/4885AKR1B1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.